Evidence map›Paper›PMID 26443453›Full record

ArticlemBio2015

Enhanced Trapping of HIV-1 by Human Cervicovaginal Mucus Is Associated with Lactobacillus crispatus-Dominant Microbiota.

Kenetta L Nunn, Ying-Ying Wang, Dimple Harit, Michael S Humphrys, Bing Ma, Richard Cone, Jacques Ravel, Samuel K Lai

Open access · goldAbstract read
In one paragraph

Article in mBio, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 199 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Innate Immune Protection Against HIV in the Female Genital Tract.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  7. Regulatory Effects ofMicroorganisms · 2026
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Bacterial vaginosis.Nature reviews. Disease primers · 2025
    Review
  17. Vaginally-delivered fast-dissolving antibody tablets (FDAT) for on-demand non-hormonal contraception and multi-purpose protection.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  18. Review
  19. Review
  20. Review

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kenetta L NunnUNC/NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Ying-Ying WangDepartment of Biophysics, Johns Hopkins University, Baltimore, Maryland, USA.
Dimple HaritDivision of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Michael S HumphrysInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Bing MaInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Richard ConeDepartment of Biophysics, Johns Hopkins University, Baltimore, Maryland, USA.
Jacques RavelInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Samuel K LaiUNC/NCSU Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA lai@unc.edu.ORCID http://orcid.org/0000-0003-4721-528X
University of Maryland, Baltimore · USUniversity of North Carolina at Chapel Hill · USJohns Hopkins University · US

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Serologic Biomarkers of Human Sexually Transmitted Infection and DiseaseU19AI084044 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI KO, DENNIS CHUN-YONE · 2009 to 2018
$22.8M
Vaginal mAB Delivery SystemsU19AI096398 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ANDERSON, DEBORAH J, MOENCH, THOMAS RAY · 2011 to 2016
$15.0M
UNC PREP in the Biomedical Sciences - Administrative SupplementR25GM089569 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBINSON, DONITA L, RODRIGUEZ-ROMAGUERA, JOSE · 2010 to 2024
$5.6M
Trapping HIV in mucus with IgG antibodiesR21AI093242 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LAI, SAMUEL · 2011 to 2012
$403k
Mechanisms regulating episodic breaches of protective vaginal microbiome by BVF32AI102535 · NIAID · JOHNS HOPKINS UNIVERSITY · PI WANG, YING-YING · 2012 to 2013
$101k
NIAID NIH HHS 1F32AI102535NIAID NIH HHS F32 AI102535NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI50410NIAID NIH HHS R21 AI093242NIAID NIH HHS R21AI093242NIAID NIH HHS U19 AI084044NIAID NIH HHS U19AI084044NIAID NIH HHS U19 AI096398NIAID NIH HHS U19AI096398NIGMS NIH HHS R25 GM089569
6 · The paper itself

Abstract

unlabelledCervicovaginal mucus (CVM) can provide a barrier that precludes HIV and other sexually transmitted virions from reaching target cells in the vaginal epithelium, thereby preventing or reducing infections. However, the barrier properties of CVM differ from woman to woman, and the causes of these variations are not yet well understood. Using high-resolution particle tracking of fluorescent HIV-1 pseudoviruses, we found that neither pH nor Nugent scores nor total lactic acid levels correlated significantly with virus trapping in unmodified CVM from diverse donors. Surprisingly, HIV-1 was generally trapped in CVM with relatively high concentrations of d-lactic acid and a Lactobacillus crispatus-dominant microbiota. In contrast, a substantial fraction of HIV-1 virions diffused rapidly through CVM with low concentrations of d-lactic acid that had a Lactobacillus iners-dominant microbiota or significant amounts of Gardnerella vaginalis, a bacterium associated with bacterial vaginosis. Our results demonstrate that the vaginal microbiota, including specific species of Lactobacillus, can alter the diffusional barrier properties of CVM against HIV and likely other sexually transmitted viruses and that these microbiota-associated changes may account in part for the elevated risks of HIV acquisition linked to bacterial vaginosis or intermediate vaginal microbiota. IMPORTANCE: Variations in the vaginal microbiota, especially shifts away from Lactobacillus-dominant microbiota, are associated with differential risks of acquiring HIV or other sexually transmitted infections. However, emerging evidence suggests that Lactobacillus iners frequently colonizes women with recurring bacterial vaginosis, raising the possibility that L. iners may not be as protective as other Lactobacillus species. Our study was designed to improve understanding of how the cervicovaginal mucus barrier against HIV may vary between women along with the vaginal microbiota and led to the finding that the vaginal microbiota, including specific species of Lactobacillus, can directly alter the diffusional barrier properties of cervicovaginal mucus. This work advances our understanding of the complex barrier properties of mucus and highlights the differential protective ability of different species of Lactobacillus, with Lactobacillus crispatus and possibly other species playing a key role in protection against HIV and other sexually transmitted infections. These findings could lead to the development of novel strategies to protect women against HIV.

Indexed as

AdultCervix UteriFemaleGardnerella vaginalisHIV-1HumansHydrogen-Ion ConcentrationLactic AcidLactobacillusMucusVaginaYoung AdultLactic Acid

Identifiers

PMID26443453
PMCPMC4611035
OpenAlexW2172682788

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.